MannKind (MNKD -11.5%) shares tumble after the company fails to win FDA approval to market its...

|About: MannKind Corporation (MNKD)|By:, SA News Editor

MannKind (MNKD -11.5%) shares tumble after the company fails to win FDA approval to market its inhaled insulin drug, Afrezza, for people with diabetes. While the regulators didn’t cite any safety concerns, they did request updated safety data, the company said. (PR)